NLS Pharmaceutics AG (NLSP)
NASDAQ: NLSP · Real-Time Price · USD
1.950
-0.100 (-4.88%)
Feb 21, 2025, 4:00 PM EST - Market closed
NLS Pharmaceutics AG Employees
As of December 31, 2021, NLS Pharmaceutics AG had 7 total employees, including 6 full-time and 1 part-time employees.
Employees
7
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$942,161
Market Cap
3.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
NLSP News
- 12 days ago - NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - PRNewsWire
- 22 days ago - Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics - PRNewsWire
- 23 days ago - NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting - PRNewsWire
- 25 days ago - NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - PRNewsWire
- 5 weeks ago - Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS - PRNewsWire
- 6 weeks ago - NLS Pharmaceutics Ltd. and Kadimastem Ltd. - PRNewsWire
- 2 months ago - NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - Accesswire
- 2 months ago - NLS Pharmaceutics CEO Issues Letter to Shareholders - Accesswire